NeuVax vaccination reduces tumor growth in mouse models
November 2016
SHARING OPTIONS:

SAN RAMON, Calif.—Biopharmaceutical company Galena Biopharma Inc. recently shared preclinical data regarding its NeuVax program at the Progress in Vaccination Against Cancer Conference. NeuVax is a first-in-class, HER2-directed cancer immunotherapy currently being assessed for its ability to prevent breast cancer recurrence after standard-of-care treatment in the adjuvant setting. The study in question featured HLA-A2 transgenic mice that were immunized with NeuVax (E75) mixed with recombinant mouse GM-CSF. CD8+ T cells from the spleens of HLA-A2 transgenic immunized mice were transferred to NSG (NOD/SCID/IL2Rγnull) mice with human ovarian or pancreatic tumors which were HER2-positive and HLA-A2-positive. NeuVax vaccination led to a specific, delayed-type hypersensitivity reaction and the induction of E75-specific CD8+ T cells that express PD-1. Growth rate for both ovarian and pancreatic tumors was significantly reduced in models of NSG mice that received the CD8+ T cells from NeuVax-immunized mice, compared to those receiving the cells from control mice.

Back
 
CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.